

August 5, 2013

Pharmacy Announcement

Preferred Drug List (PDL) Changes Effective August 5, 2013

On June 27, 2013, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective August 5, 2013. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added as Preferred	Drugs Added as Non-Preferred
CENTRAL NERVOUS SYSTEM: ADHD/Stimulants	Quillivant XR® SUSP Strattera®*	
CENTRAL NERVOUS SYSTEM: Oral Anticonvulsants, Misc.		Oxtellar XR®
GASTROINTESTINAL AGENTS: Ulcerative Colitis	Delzicol®	Asacol HD® Lialda®
MULTIPLE SCLEROSIS AGENTS: Disease Modifying**	Extavia® Tecfidera® Tysabri®	Aubagio® Gilenya®

*The P&T Committee voted to include Strattera® as preferred for all ages. Previously it was preferred for age 18 and older only.

**The P&T Committee voted to require a trial of only one preferred agent in this drug class before moving to a non-preferred agent, instead of the usual two agents.